Spotlight on Dermatology

Credits: 0.75 CME / MOC
The Lupus Hub: Primary Care’s Pivotal Role in SLE
Louis Kuritzky, MD
The France Foundation

The Lupus Hub: Primary Care’s Pivotal Role in SLE

Start

Activity Details

Free CME/MOC
.75 AMA PRA Category 1 Credit(s)™/
MOC point(s)
Released: December 18, 2018
Expires: December 17, 2019
45 minutes to complete

Accredited By

Target Audience

This educational initiative is intended for primary care clinicians who care for adult patients with SLE.

Learning Objectives

  1. Describe key evidence-based strategies for diagnosing SLE.
  2. Utilize effective strategies to assess and co-manage patients with SLE over time.
  3. Summarize key aspects of established treatments for SLE.
  4. Monitor the patient for treatment side effects.
  5. Formulate a plan for communication with patients about SLE and its treatment, including methods for facilitating treatment adherence.

Activity Description

Autoimmune diseases are difficult to diagnose. Lupus, in particular, is complicated as its symptoms are common to a variety of other conditions. Diagnosing lupus with any degree of accuracy can be challenging and costly. This activity will orient the primary care provider on how to accurately diagnose systemic lupus erythematosus (SLE), further providing guidance on management strategies and doctor-patient communication, specifically with the goal of increasing treatment adherence in patients.

Agenda

  1. Recognizing SLE: Primary Care Approach to Diagnostic Criteria
    How to recognize the condition based on ACR criteria.
  2. Assessing a Moving Target: SLE Evaluation Over Time
    Signs of disease progression; when to recommend further evaluation.
  3. Answering the “Whats” and “Whens” of Management
    Understanding treatment options, facilitating specialist consultation, and monitoring for treatment side effects.
  4. Keeping the Lines Open: Practical Strategies for Communication and Facilitating Adherence
    What are effective communication techniques (eg, AHRQ’s “Teach Back” method, particular phrasing for adherence-related questions, encouraging patient-generated questions) that can address sensitive or challenging issues? Applying practical patient-centered approaches as a means to facilitate treatment adherence.

Faculty

Louis Kuritzky, MD
Louis Kuritzky, MD
Content Creator and Activity Presenter
Clinical Assistant Professor Emeritus
Department of Community Health and Family Medicine
University of Florida, Gainesville
Gainesville, Florida

Disclosure:
Louis Kurtizky, MD, has no relevant financial relationships to disclose.


Daniel J. Wallace, MD, FACP, MACR
Daniel J. Wallace, MD, FACP, MACR
Content Creator
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
In affiliation with Attune Health
Los Angeles, California

Disclosure:
Daniel J. Wallace, MD, FACP, MACR, has served as an advisor for Amgen, EMD Serono, Celgene, Merck, Lilly.


MOC Reviewer

Richard Sadovsky, MD, MS
Associate Professor of Family Medicine
SUNY-Downstate Medical center

Disclosure:
Richard Sadovsky, MD, has no relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. The France Foundation resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, The France Foundation seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. The France Foundation is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation requires CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. The France Foundation does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions about the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/MOC
.75 AMA PRA Category 1 Credit(s)™/
MOC point(s)
Released: December 18, 2018
Expires: December 17, 2019
45 minutes to complete

Accredited By

Target Audience

This educational initiative is intended for primary care clinicians who care for adult patients with SLE.

Learning Objectives

  1. Describe key evidence-based strategies for diagnosing SLE.
  2. Utilize effective strategies to assess and co-manage patients with SLE over time.
  3. Summarize key aspects of established treatments for SLE.
  4. Monitor the patient for treatment side effects.
  5. Formulate a plan for communication with patients about SLE and its treatment, including methods for facilitating treatment adherence.

Activity Description

Autoimmune diseases are difficult to diagnose. Lupus, in particular, is complicated as its symptoms are common to a variety of other conditions. Diagnosing lupus with any degree of accuracy can be challenging and costly. This activity will orient the primary care provider on how to accurately diagnose systemic lupus erythematosus (SLE), further providing guidance on management strategies and doctor-patient communication, specifically with the goal of increasing treatment adherence in patients.

Agenda

  1. Recognizing SLE: Primary Care Approach to Diagnostic Criteria
    How to recognize the condition based on ACR criteria.
  2. Assessing a Moving Target: SLE Evaluation Over Time
    Signs of disease progression; when to recommend further evaluation.
  3. Answering the “Whats” and “Whens” of Management
    Understanding treatment options, facilitating specialist consultation, and monitoring for treatment side effects.
  4. Keeping the Lines Open: Practical Strategies for Communication and Facilitating Adherence
    What are effective communication techniques (eg, AHRQ’s “Teach Back” method, particular phrasing for adherence-related questions, encouraging patient-generated questions) that can address sensitive or challenging issues? Applying practical patient-centered approaches as a means to facilitate treatment adherence.

Faculty

Louis Kuritzky, MD
Louis Kuritzky, MD
Content Creator and Activity Presenter
Clinical Assistant Professor Emeritus
Department of Community Health and Family Medicine
University of Florida, Gainesville
Gainesville, Florida

Disclosure:
Louis Kurtizky, MD, has no relevant financial relationships to disclose.


Daniel J. Wallace, MD, FACP, MACR
Daniel J. Wallace, MD, FACP, MACR
Content Creator
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
In affiliation with Attune Health
Los Angeles, California

Disclosure:
Daniel J. Wallace, MD, FACP, MACR, has served as an advisor for Amgen, EMD Serono, Celgene, Merck, Lilly.


MOC Reviewer

Richard Sadovsky, MD, MS
Associate Professor of Family Medicine
SUNY-Downstate Medical center

Disclosure:
Richard Sadovsky, MD, has no relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. The France Foundation resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, The France Foundation seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. The France Foundation is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation requires CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. The France Foundation does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions about the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Dermatology Presentations

1.25 CME
Vindico
Recognition and Management of Pemphigus Vulgaris: The Central Role of the Dental Provider in Coordinating Multidisciplinary Care

Recognition and Management of Pemphigus Vulgaris: The Central Role of the Dental Provider in Coordinating Multidisciplinary Care

Start

Activity Details

Free CME
1.25 AMA PRA Category 1 Credits
Released: November 14, 2019
Expires: November 13, 2020
75 minutes to complete

Provided By

This continuing medical education activity is jointly provided by
  and  

Target Audience

The intended audience for this activity is dentists, dental hygienists, dermatologists, rheumatologists, and other health care professionals involved in the management of patients with pemphigus vulgaris (PV).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
  • Examine the clinical symptomology of PV as well as the impact of disease on patient quality of life.
  • Review strategies for the timely identification and referral of patients with suspected PV.
  • Review current treatment paradigms for patients with PV.
  • Evaluate effective approaches for the multidisciplinary care of patients with PV.

Activity Description

Pemphigus vulgaris (PV) is a chronic, blistering disorder that affects approximately 30,000 individuals in the United States. In almost 80% of cases, the first sign of disease is oral blistering, so dentists often play a key role in the referral of patients. In nearly half of patients, lesions spread, with nasal and/or laryngeal involvement. Blistering of the skin may occur on any part of the body and is often accompanied by burning, pain, itching, or stinging, with a significant adverse impact on quality of life and mental health. Dental providers must work closely with rheumatologists and dermatologists to recognize and differentially diagnose patients with PV. In this activity, the central role of the dental provider in coordinating multidisciplinary care of patients with PV will be addressed, as well as the clinical symptomology and current treatment paradigms of PV.

Activity Chair

Ronald M. Harris, MD, MBA, FAAD
Principal, Integrated Dermatology of Yuma, PLLC
Health Sciences Clinical Professor of Dermatology
Department of Dermatology
University of California, Irvine
Irvine, CA

Disclosures
Consulting Fee: Genentech
Speakers Bureau: Genentech


Faculty

Annette Czernik, MD
Assistant Professor, Department of Dermatology
Clinical Director, Mount Sinai Dermatology Faculty Practice
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures
Speakers Bureau: Genentech


Thomas P. Sollecito, DMD, FDS RCSEd
Professor and Chair of Oral Medicine
Associate Dean of Hospital Affairs
University of Pennsylvania
School of Dental Medicine
Chief, Oral Medicine
University of Pennsylvania Health System
Philadelphia, PA

Disclosures
Contracted Research: AFYX Therapeutics


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Nanette C. Tertel, DDS
No relevant financial relationships to disclose.

Staff
The American Dental Association
No relevant financial relationships to disclose.

Vindico Medical Education
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers, and staff involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Vindico Medical Education and the American Dental Association. Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, November 14, 2019 to November 13, 2020.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the presentations, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 out of 5 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA–approved or investigational use of products/devices.

Copyright and Disclaimer

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

The material presented at or in any of the American Dental Association and Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of the American Dental Association and Vindico Medical Education. Neither the American Dental Association, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty may discuss the use of materials and/or products that have not yet been approved by the U.S. Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.25 AMA PRA Category 1 Credits
Released: November 14, 2019
Expires: November 13, 2020
75 minutes to complete

Provided By

This continuing medical education activity is jointly provided by
  and  

Target Audience

The intended audience for this activity is dentists, dental hygienists, dermatologists, rheumatologists, and other health care professionals involved in the management of patients with pemphigus vulgaris (PV).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
  • Examine the clinical symptomology of PV as well as the impact of disease on patient quality of life.
  • Review strategies for the timely identification and referral of patients with suspected PV.
  • Review current treatment paradigms for patients with PV.
  • Evaluate effective approaches for the multidisciplinary care of patients with PV.

Activity Description

Pemphigus vulgaris (PV) is a chronic, blistering disorder that affects approximately 30,000 individuals in the United States. In almost 80% of cases, the first sign of disease is oral blistering, so dentists often play a key role in the referral of patients. In nearly half of patients, lesions spread, with nasal and/or laryngeal involvement. Blistering of the skin may occur on any part of the body and is often accompanied by burning, pain, itching, or stinging, with a significant adverse impact on quality of life and mental health. Dental providers must work closely with rheumatologists and dermatologists to recognize and differentially diagnose patients with PV. In this activity, the central role of the dental provider in coordinating multidisciplinary care of patients with PV will be addressed, as well as the clinical symptomology and current treatment paradigms of PV.

Activity Chair

Ronald M. Harris, MD, MBA, FAAD
Principal, Integrated Dermatology of Yuma, PLLC
Health Sciences Clinical Professor of Dermatology
Department of Dermatology
University of California, Irvine
Irvine, CA

Disclosures
Consulting Fee: Genentech
Speakers Bureau: Genentech


Faculty

Annette Czernik, MD
Assistant Professor, Department of Dermatology
Clinical Director, Mount Sinai Dermatology Faculty Practice
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures
Speakers Bureau: Genentech


Thomas P. Sollecito, DMD, FDS RCSEd
Professor and Chair of Oral Medicine
Associate Dean of Hospital Affairs
University of Pennsylvania
School of Dental Medicine
Chief, Oral Medicine
University of Pennsylvania Health System
Philadelphia, PA

Disclosures
Contracted Research: AFYX Therapeutics


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Nanette C. Tertel, DDS
No relevant financial relationships to disclose.

Staff
The American Dental Association
No relevant financial relationships to disclose.

Vindico Medical Education
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers, and staff involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Vindico Medical Education and the American Dental Association. Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, November 14, 2019 to November 13, 2020.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the presentations, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 out of 5 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA–approved or investigational use of products/devices.

Copyright and Disclaimer

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

The material presented at or in any of the American Dental Association and Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of the American Dental Association and Vindico Medical Education. Neither the American Dental Association, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty may discuss the use of materials and/or products that have not yet been approved by the U.S. Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at CME@VindicoCME.com

0.50 CME / MOC
Vindico
MedEdTalks Rheumatology: 3rd Annual Association of Women in Rheumatology National Conference: Immunology Bootcamp – Lupus

MedEdTalks Rheumatology: 3rd Annual Association of Women in Rheumatology National Conference: Immunology Bootcamp – Lupus

Start

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)™/
MOC point(s)
Released: October 28, 2019
Expires: October 27, 2020
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).

Learning Objective

Upon successful completion of this activity, participants should be better able to evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.

Activity Description

In this CME podcast, Dr. Grace Wright and Dr. John Tesser will discuss the diagnosis and treatment of systemic lupus erythematosus.

Faculty

Activity Chair
Grace C. Wright, MD, PhD, FACR
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB


Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB


Jeffrey L. Kaine, MD
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer


John R.P. Tesser, MD
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.

Staff
Vindico Medical Education
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers, and staff involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

This enduring material is approved for 1 year from the date of original release, October 28, 2019 to October 27, 2020.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)™/
MOC point(s)
Released: October 28, 2019
Expires: October 27, 2020
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).

Learning Objective

Upon successful completion of this activity, participants should be better able to evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.

Activity Description

In this CME podcast, Dr. Grace Wright and Dr. John Tesser will discuss the diagnosis and treatment of systemic lupus erythematosus.

Faculty

Activity Chair
Grace C. Wright, MD, PhD, FACR
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB


Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB


Jeffrey L. Kaine, MD
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer


John R.P. Tesser, MD
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.

Staff
Vindico Medical Education
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers, and staff involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

This enduring material is approved for 1 year from the date of original release, October 28, 2019 to October 27, 2020.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at CME@VindicoCME.com

1.00 CME
Vindico
Managing Pemphigus Vulgaris: Targeted Strategies That Improve Outcomes

Managing Pemphigus Vulgaris: Targeted Strategies That Improve Outcomes

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: August 13, 2019
Expires: August 12, 2020
1.0 hour to complete

Accredited By

This continuing medical education activity is provided by Vindico Medical Education.

Activity Chair

Anthony P. Fernandez, MD, PhD
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology
Departments of Dermatology and Pathology
Co-Medical Director of Continuing Medical Education
Cleveland Clinic
Cleveland, OH
  • Disclosure: Principal Investigator (paid to institution): Roche


Faculty

Thomas P. Sollecito, DMD, FDS, RCSEd
Professor and Chair of Oral Medicine
Associate Dean of Hospital Affairs
University of Pennsylvania
School of Dental Medicine
Chief of Oral Medicine
University of Pennsylvania Health System
Philadelphia, PA
  • Disclosure: Contracted Research: AFYX Therapeutics


Victoria Werth, MD
Professor of Dermatology and Medicine 
Chief, Dermatology
Hospital of the University of Pennsylvania
Veteran’s Administration Medical Center 
Philadelphia, PA
  • Disclosure: Consulting Fee: Amgen, Biogen, Bristol-Myers Squibb, Celgene, Crisalis, CSL Behring, EMD Serono, Genentech, Gilead, Idera, Incyte, Janssen, Lilly, MedImmune, Medscape, Nektar, Pfizer, Principia, Resolve, Vielo
    Contracted Research: AstraZeneca, Biogen, Celgene, Corbus, Genentech, Gilead, Janssen, Pfizer, Vielo


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Activity Description

Autoimmune bullous diseases involve autoimmunity against structural components that maintain cell-cell and cell-matrix adhesion in the skin and mucous membranes. Such diseases include those in which blistering occurs at the basement membrane zone and those in which blistering occurs within the epidermis. Of these, pemphigus involves both the skin and mucosal membranes. Pemphigus vulgaris (PV) is, by far, the most common subtype, accounting for approximately 80% of all pemphigus cases. This rare, chronic disease affects approximately 30,000 to 40,000 individuals in the United States and can have a significant impact on quality of life. In this continuing education activity, expert clinicians will examine the epidemiology, diagnosis, and treatment of PV, as well as effective approaches for the multidisciplinary care of patients with PV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Summarize the characteristics, epidemiology, and impact of pemphigus vulgaris (PV) on patients’ quality of life
  • Assess the benefits and limitations of conventional and newer treatment strategies for PV
  • Implement effective approaches for the multidisciplinary care of patients with PV

Target Audience

The intended audience for the activity is dermatologists and other health care professionals involved in the treatment of patients with pemphigus vulgaris.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity:
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the Merit-Based Incentive Payment System (MIPS) of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Disclaimer

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: August 13, 2019
Expires: August 12, 2020
1.0 hour to complete

Accredited By

This continuing medical education activity is provided by Vindico Medical Education.

Activity Chair

Anthony P. Fernandez, MD, PhD
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology
Departments of Dermatology and Pathology
Co-Medical Director of Continuing Medical Education
Cleveland Clinic
Cleveland, OH
  • Disclosure: Principal Investigator (paid to institution): Roche


Faculty

Thomas P. Sollecito, DMD, FDS, RCSEd
Professor and Chair of Oral Medicine
Associate Dean of Hospital Affairs
University of Pennsylvania
School of Dental Medicine
Chief of Oral Medicine
University of Pennsylvania Health System
Philadelphia, PA
  • Disclosure: Contracted Research: AFYX Therapeutics


Victoria Werth, MD
Professor of Dermatology and Medicine 
Chief, Dermatology
Hospital of the University of Pennsylvania
Veteran’s Administration Medical Center 
Philadelphia, PA
  • Disclosure: Consulting Fee: Amgen, Biogen, Bristol-Myers Squibb, Celgene, Crisalis, CSL Behring, EMD Serono, Genentech, Gilead, Idera, Incyte, Janssen, Lilly, MedImmune, Medscape, Nektar, Pfizer, Principia, Resolve, Vielo
    Contracted Research: AstraZeneca, Biogen, Celgene, Corbus, Genentech, Gilead, Janssen, Pfizer, Vielo


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Activity Description

Autoimmune bullous diseases involve autoimmunity against structural components that maintain cell-cell and cell-matrix adhesion in the skin and mucous membranes. Such diseases include those in which blistering occurs at the basement membrane zone and those in which blistering occurs within the epidermis. Of these, pemphigus involves both the skin and mucosal membranes. Pemphigus vulgaris (PV) is, by far, the most common subtype, accounting for approximately 80% of all pemphigus cases. This rare, chronic disease affects approximately 30,000 to 40,000 individuals in the United States and can have a significant impact on quality of life. In this continuing education activity, expert clinicians will examine the epidemiology, diagnosis, and treatment of PV, as well as effective approaches for the multidisciplinary care of patients with PV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Summarize the characteristics, epidemiology, and impact of pemphigus vulgaris (PV) on patients’ quality of life
  • Assess the benefits and limitations of conventional and newer treatment strategies for PV
  • Implement effective approaches for the multidisciplinary care of patients with PV

Target Audience

The intended audience for the activity is dermatologists and other health care professionals involved in the treatment of patients with pemphigus vulgaris.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity:
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the Merit-Based Incentive Payment System (MIPS) of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Disclaimer

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

1.00 CME
Vindico
Chronic Idiopathic Urticaria: Improving Treatment, With a Focus on Patient Outcomes

Chronic Idiopathic Urticaria: Improving Treatment, With a Focus on Patient Outcomes

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: April 18, 2019
Expires: April 17, 2020
1 hour to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists and other health care professionals involved in the treatment of patients with chronic idiopathic urticaria (CIU).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Assess the impact of chronic idiopathic urticaria (CIU) on quality of life, including sleep, psychological functioning, work and activity.
  • Compare the strengths and limitations of current guideline approaches to the management of CIU.
  • Select treatment options for patients with CIU who fail to achieve complete symptom control with first- and second-line therapy.

Activity Description

Urticaria, a common skin condition characterized by transient pruritic wheals, occurs in 20% to 25% of individuals within their lifetimes. Urticaria can be classified by both symptom duration and underlying etiology. Patients who experience symptom recurrence for a duration over 6 weeks may be diagnosed as having chronic idiopathic urticaria (CIU). CIU negatively impacts physical functioning, work performance, emotional well-being, and overall quality of life, with an impact similar in magnitude to that experienced by patients with coronary disease awaiting bypass surgery. A US practice guideline issued in 2014 and an updated international guideline issued in 2018 are available to guide diagnosis and treatment of urticaria. Although the recommendations in these guidelines largely overlap, specialists need to be knowledgeable about their strengths and limitations to select optimal treatment strategies for their patients. This CME activity will assess the impact of CIU on quality of life, particularly its impact on sleep, psychological functioning, work, and activity. Current guideline approaches to the management of CIU will be evaluated, as well as treatment options for patients with CIU who fail to achieve complete symptom control with first- and second-line therapy.

Activity Chair

Jonathan A. Bernstein, MD
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology, Allergy Section
Editor in Chief, Journal of Asthma
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Cincinnati, OH

Disclosures
Royalty: CRC Press, Springer Publishing
Intellectual Property/Patent Details: University of Cincinnati
Consulting Fee: ALK, AstraZeneca, BioCryst, CSL Behring, Genentech, Merck, Novartis, Optinose, Pharming, Regeneron, Sanofi, Shire
Speakers Bureau: ALK, AstraZeneca, CSL Behring, Novartis, Optinose, Pharming, Sanofi, Shire
Contracted Research: AstraZeneca, BioCryst, CSL Behring, Merck, Novartis/Genentech, Optinose, Pharming, Sanofi, Shire


Faculty

David A. Khan, MD
Professor of Medicine and Pediatrics
Allergy and Immunology Program Director
University of Texas Southwestern Medical Center
Dallas, TX

Disclosures
Royalty: Elsevier, UpToDate
Speakers Bureau: Genentech
Data Safety Monitoring Committee: Aimmune


Prof. Dr. med. Dr. hc Torsten Zuberbier
Head of the Allergy Center Charité - Dermatology Clinic
Spokesman for the Comprehensive Allergy Center Charité
Allergy Center Charité
Charité - Universitätsmedizin Berlin
Berlin, Germany

Disclosures
Consulting Fee: AbbVie, ALK, Almirall, Astellas, AstraZeneca, Bayer, Bencard, Berlin-Chemie, FAES, HAL Allergy, Henkel, Kryolan, Leti, L'Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes Greer, Takeda, Teva, UCB
Speakers Bureau: AbbVie, ALK, Almirall, Astellas, AstraZeneca, Bayer, Bencard, Berlin-Chemie, FAES, HAL Allergy, Henkel, Kryolan, Leti, L'Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes Greer, Takeda, Teva, UCB
Committee Member: WHO-Initiative "Allergic Rhinitis and its Impact on Asthma" (ARIA)
Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI)
Head: European Centre for Allergy Research Foundation (ECARF)
Secretary General: Global Allergy and Asthma European Network (GA2LEN)
Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organisation (WAO)


Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Staff
Vindico Medical Education
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers and staff involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, April 18, 2019 to April 17, 2020.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the presentations, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Participation Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Contact Information for Questions about the Activity

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: April 18, 2019
Expires: April 17, 2020
1 hour to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists and other health care professionals involved in the treatment of patients with chronic idiopathic urticaria (CIU).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Assess the impact of chronic idiopathic urticaria (CIU) on quality of life, including sleep, psychological functioning, work and activity.
  • Compare the strengths and limitations of current guideline approaches to the management of CIU.
  • Select treatment options for patients with CIU who fail to achieve complete symptom control with first- and second-line therapy.

Activity Description

Urticaria, a common skin condition characterized by transient pruritic wheals, occurs in 20% to 25% of individuals within their lifetimes. Urticaria can be classified by both symptom duration and underlying etiology. Patients who experience symptom recurrence for a duration over 6 weeks may be diagnosed as having chronic idiopathic urticaria (CIU). CIU negatively impacts physical functioning, work performance, emotional well-being, and overall quality of life, with an impact similar in magnitude to that experienced by patients with coronary disease awaiting bypass surgery. A US practice guideline issued in 2014 and an updated international guideline issued in 2018 are available to guide diagnosis and treatment of urticaria. Although the recommendations in these guidelines largely overlap, specialists need to be knowledgeable about their strengths and limitations to select optimal treatment strategies for their patients. This CME activity will assess the impact of CIU on quality of life, particularly its impact on sleep, psychological functioning, work, and activity. Current guideline approaches to the management of CIU will be evaluated, as well as treatment options for patients with CIU who fail to achieve complete symptom control with first- and second-line therapy.

Activity Chair

Jonathan A. Bernstein, MD
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology, Allergy Section
Editor in Chief, Journal of Asthma
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Cincinnati, OH

Disclosures
Royalty: CRC Press, Springer Publishing
Intellectual Property/Patent Details: University of Cincinnati
Consulting Fee: ALK, AstraZeneca, BioCryst, CSL Behring, Genentech, Merck, Novartis, Optinose, Pharming, Regeneron, Sanofi, Shire
Speakers Bureau: ALK, AstraZeneca, CSL Behring, Novartis, Optinose, Pharming, Sanofi, Shire
Contracted Research: AstraZeneca, BioCryst, CSL Behring, Merck, Novartis/Genentech, Optinose, Pharming, Sanofi, Shire


Faculty

David A. Khan, MD
Professor of Medicine and Pediatrics
Allergy and Immunology Program Director
University of Texas Southwestern Medical Center
Dallas, TX

Disclosures
Royalty: Elsevier, UpToDate
Speakers Bureau: Genentech
Data Safety Monitoring Committee: Aimmune


Prof. Dr. med. Dr. hc Torsten Zuberbier
Head of the Allergy Center Charité - Dermatology Clinic
Spokesman for the Comprehensive Allergy Center Charité
Allergy Center Charité
Charité - Universitätsmedizin Berlin
Berlin, Germany

Disclosures
Consulting Fee: AbbVie, ALK, Almirall, Astellas, AstraZeneca, Bayer, Bencard, Berlin-Chemie, FAES, HAL Allergy, Henkel, Kryolan, Leti, L'Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes Greer, Takeda, Teva, UCB
Speakers Bureau: AbbVie, ALK, Almirall, Astellas, AstraZeneca, Bayer, Bencard, Berlin-Chemie, FAES, HAL Allergy, Henkel, Kryolan, Leti, L'Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes Greer, Takeda, Teva, UCB
Committee Member: WHO-Initiative "Allergic Rhinitis and its Impact on Asthma" (ARIA)
Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI)
Head: European Centre for Allergy Research Foundation (ECARF)
Secretary General: Global Allergy and Asthma European Network (GA2LEN)
Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organisation (WAO)


Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Staff
Vindico Medical Education
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers and staff involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, April 18, 2019 to April 17, 2020.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the presentations, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Participation Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Contact Information for Questions about the Activity

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at CME@VindicoCME.com

0.75 CME / MOC
The France Foundation
The Lupus Hub: Primary Care’s Pivotal Role in SLE

The Lupus Hub: Primary Care’s Pivotal Role in SLE

Start

Activity Details

Free CME/MOC
.75 AMA PRA Category 1 Credit(s)™/
MOC point(s)
Released: December 18, 2018
Expires: December 17, 2019
45 minutes to complete

Accredited By

Target Audience

This educational initiative is intended for primary care clinicians who care for adult patients with SLE.

Learning Objectives

  1. Describe key evidence-based strategies for diagnosing SLE.
  2. Utilize effective strategies to assess and co-manage patients with SLE over time.
  3. Summarize key aspects of established treatments for SLE.
  4. Monitor the patient for treatment side effects.
  5. Formulate a plan for communication with patients about SLE and its treatment, including methods for facilitating treatment adherence.

Activity Description

Autoimmune diseases are difficult to diagnose. Lupus, in particular, is complicated as its symptoms are common to a variety of other conditions. Diagnosing lupus with any degree of accuracy can be challenging and costly. This activity will orient the primary care provider on how to accurately diagnose systemic lupus erythematosus (SLE), further providing guidance on management strategies and doctor-patient communication, specifically with the goal of increasing treatment adherence in patients.

Agenda

  1. Recognizing SLE: Primary Care Approach to Diagnostic Criteria
    How to recognize the condition based on ACR criteria.
  2. Assessing a Moving Target: SLE Evaluation Over Time
    Signs of disease progression; when to recommend further evaluation.
  3. Answering the “Whats” and “Whens” of Management
    Understanding treatment options, facilitating specialist consultation, and monitoring for treatment side effects.
  4. Keeping the Lines Open: Practical Strategies for Communication and Facilitating Adherence
    What are effective communication techniques (eg, AHRQ’s “Teach Back” method, particular phrasing for adherence-related questions, encouraging patient-generated questions) that can address sensitive or challenging issues? Applying practical patient-centered approaches as a means to facilitate treatment adherence.

Faculty

Louis Kuritzky, MD
Louis Kuritzky, MD
Content Creator and Activity Presenter
Clinical Assistant Professor Emeritus
Department of Community Health and Family Medicine
University of Florida, Gainesville
Gainesville, Florida

Disclosure:
Louis Kurtizky, MD, has no relevant financial relationships to disclose.


Daniel J. Wallace, MD, FACP, MACR
Daniel J. Wallace, MD, FACP, MACR
Content Creator
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
In affiliation with Attune Health
Los Angeles, California

Disclosure:
Daniel J. Wallace, MD, FACP, MACR, has served as an advisor for Amgen, EMD Serono, Celgene, Merck, Lilly.


MOC Reviewer

Richard Sadovsky, MD, MS
Associate Professor of Family Medicine
SUNY-Downstate Medical center

Disclosure:
Richard Sadovsky, MD, has no relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. The France Foundation resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, The France Foundation seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. The France Foundation is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation requires CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. The France Foundation does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions about the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/MOC
.75 AMA PRA Category 1 Credit(s)™/
MOC point(s)
Released: December 18, 2018
Expires: December 17, 2019
45 minutes to complete

Accredited By

Target Audience

This educational initiative is intended for primary care clinicians who care for adult patients with SLE.

Learning Objectives

  1. Describe key evidence-based strategies for diagnosing SLE.
  2. Utilize effective strategies to assess and co-manage patients with SLE over time.
  3. Summarize key aspects of established treatments for SLE.
  4. Monitor the patient for treatment side effects.
  5. Formulate a plan for communication with patients about SLE and its treatment, including methods for facilitating treatment adherence.

Activity Description

Autoimmune diseases are difficult to diagnose. Lupus, in particular, is complicated as its symptoms are common to a variety of other conditions. Diagnosing lupus with any degree of accuracy can be challenging and costly. This activity will orient the primary care provider on how to accurately diagnose systemic lupus erythematosus (SLE), further providing guidance on management strategies and doctor-patient communication, specifically with the goal of increasing treatment adherence in patients.

Agenda

  1. Recognizing SLE: Primary Care Approach to Diagnostic Criteria
    How to recognize the condition based on ACR criteria.
  2. Assessing a Moving Target: SLE Evaluation Over Time
    Signs of disease progression; when to recommend further evaluation.
  3. Answering the “Whats” and “Whens” of Management
    Understanding treatment options, facilitating specialist consultation, and monitoring for treatment side effects.
  4. Keeping the Lines Open: Practical Strategies for Communication and Facilitating Adherence
    What are effective communication techniques (eg, AHRQ’s “Teach Back” method, particular phrasing for adherence-related questions, encouraging patient-generated questions) that can address sensitive or challenging issues? Applying practical patient-centered approaches as a means to facilitate treatment adherence.

Faculty

Louis Kuritzky, MD
Louis Kuritzky, MD
Content Creator and Activity Presenter
Clinical Assistant Professor Emeritus
Department of Community Health and Family Medicine
University of Florida, Gainesville
Gainesville, Florida

Disclosure:
Louis Kurtizky, MD, has no relevant financial relationships to disclose.


Daniel J. Wallace, MD, FACP, MACR
Daniel J. Wallace, MD, FACP, MACR
Content Creator
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
In affiliation with Attune Health
Los Angeles, California

Disclosure:
Daniel J. Wallace, MD, FACP, MACR, has served as an advisor for Amgen, EMD Serono, Celgene, Merck, Lilly.


MOC Reviewer

Richard Sadovsky, MD, MS
Associate Professor of Family Medicine
SUNY-Downstate Medical center

Disclosure:
Richard Sadovsky, MD, has no relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. The France Foundation resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, The France Foundation seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. The France Foundation is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation requires CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. The France Foundation does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions about the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME
Global Education Group
Evolving Management Strategies for Moderate-to-Severe Atopic Dermatitis: Looking Beyond Barriers to Optimize Therapy

Evolving Management Strategies for Moderate-to-Severe Atopic Dermatitis: Looking Beyond Barriers to Optimize Therapy

Start
Free CME
1.0 AMA PRA Category 1 Credit
Released: December 14, 2018
Expires: December 13, 2019
60 minutes to complete

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of dermatologists, allergists, and other clinicians who treat patients with atopic dermatitis.

Statement of Need

Atopic dermatitis is a common, chronic inflammatory disease that manifests primarily in the skin, although research has uncovered potentially deleterious effects in other organ systems throughout the body.1,2 The disease-related physical and biopsychosocial burdens of atopic dermatitis can have a substantial effect on patients’ quality of life, particularly in those with moderate-to-severe disease.3,4 A better understanding of atopic dermatitis etiology has supported the development of new approaches to disease characterization and targeted therapies.5,6 As a result, the first biologic therapy is now available to treat patients with moderate-to-severe disease, and several other therapies are in late-stage clinical development.7-10 With novel therapies emerging for patients with difficult-to-treat atopic dermatitis, dermatologists will benefit from updates on the latest clinical trial data and practical recommendations on how to translate those results into daily clinical decision-making. In this Evidence-Based Best Practices™ program, internationally recognized experts will review the latest published evidence with a goal of providing recommendations to enhance overall patient outcomes. The expert faculty panel will discuss the pathophysiologic underpinnings of atopic dermatitis, share best practices related to comprehensive patient evaluations, and relay their own clinical experience in managing patients with moderate-to-severe disease.

References

  • Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(suppl 1):8-16.
  • Brunner PM, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25.
  • Whiteley J, et al. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1-7. [Epub ahead of print].
  • Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
  • Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858-873.
  • Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
  • Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  • de Bruin-Weller M, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083-1101.
  • Boguniewicz M. Biologic therapy for atopic dermatitis: moving beyond the practice parameter and guidelines. J Allergy Clin Immunol Pract. 2017;5(6):1477-1487.
  • Cotter DG, et al. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78(3S1):S53-S62.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Discuss atopic dermatitis pathophysiology, including clinically relevant molecular and cellular targets
  • Assess patients with atopic dermatitis longitudinally for uncontrolled symptoms, disease flares, comorbidities, and clinical responses to their current treatment regimens
  • Describe the clinical profiles of targeted biologic therapies for the treatment of moderate-to-severe atopic dermatitis
  • Optimize treatment regimens for patients with moderate-to-severe atopic dermatitis to reduce symptomatology, address comorbidities, maximize health-related quality of life, and minimize treatment-related side effects
  • Educate patients and caregivers to improve their understanding of atopic dermatitis to promote shared decision-making and treatment adherence

Faculty

Marjolein de Bruin-Weller, MD, PhD
Head, National Expertise Center for Atopic Dermatitis
Department of Dermatology/Allergology
University Medical Center Utrecht
Utrecht, The Netherlands



Eric L. Simpson, MD, MCR
Professor of Dermatology
Director, Clinical Research
Department of Dermatology
Oregon Health & Science University
Portland, Oregon, USA



Andreas Wollenberg, MD, PhD
Professor
Department of Dermatology and Allergy
Ludwig-Maximilian University of Munich
Munich, Germany


Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 70% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Marjolein de Bruin-Weller, MD, PhD

  • Consultant/Advisor: AbbVie Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme
  • Grant/Research Support: Regeneron Pharmaceuticals, Inc., Sanofi Genzyme.

Eric L. Simpson, MD, MCR

  • Consultant/Advisor: AbbVie Inc., Eli Lilly and Company, Galderma Laboratories, L.P., LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme.
  • Grant/Research Support: Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Vanda Pharmaceuticals Inc.

Andreas Wollenberg, MD, PhD

  • Consultant/Advisor: Almirall Limited, Beiersdorf AG, Galderma S.A., LEO Pharma Inc., L’Oréal S.A., MedImmune, LLC, Pierre Fabre Laboratories, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi-Aventis Europe S.A.S.
  • Grant/Research Support: Beiersdorf AG, LEO Pharma Inc.
  • Speakers Bureau: Almirall Limited, Anacor Pharmaceuticals, Inc., Astellas Pharma Europe Ltd, Beierdsorf AG, Bioderma Laboratoire Dermatologique, Celgene Corporation, Chugai Pharmaceutical Co., Ltd., Galderma S.A., Hans Karrer GMBH, LEO Pharma Inc., L’Oréal S.A., Meda AB, MedImmune, LLC, Merck Sharp & Dohme Corp., Novartis Pharma AG, Pierre Fabre Laboratories, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi-Aventis Europe S.A.S.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Stacey Ullman, MHS
Nothing to disclose

Ashley Marostica, RN, MSN
Nothing to disclose

Lindsay Borvansky
Nothing to disclose

Andrea Funk
Nothing to disclose

Liddy Knight
Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Free CME
1.0 AMA PRA Category 1 Credit
Released: December 14, 2018
Expires: December 13, 2019
60 minutes to complete

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of dermatologists, allergists, and other clinicians who treat patients with atopic dermatitis.

Statement of Need

Atopic dermatitis is a common, chronic inflammatory disease that manifests primarily in the skin, although research has uncovered potentially deleterious effects in other organ systems throughout the body.1,2 The disease-related physical and biopsychosocial burdens of atopic dermatitis can have a substantial effect on patients’ quality of life, particularly in those with moderate-to-severe disease.3,4 A better understanding of atopic dermatitis etiology has supported the development of new approaches to disease characterization and targeted therapies.5,6 As a result, the first biologic therapy is now available to treat patients with moderate-to-severe disease, and several other therapies are in late-stage clinical development.7-10 With novel therapies emerging for patients with difficult-to-treat atopic dermatitis, dermatologists will benefit from updates on the latest clinical trial data and practical recommendations on how to translate those results into daily clinical decision-making. In this Evidence-Based Best Practices™ program, internationally recognized experts will review the latest published evidence with a goal of providing recommendations to enhance overall patient outcomes. The expert faculty panel will discuss the pathophysiologic underpinnings of atopic dermatitis, share best practices related to comprehensive patient evaluations, and relay their own clinical experience in managing patients with moderate-to-severe disease.

References

  • Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(suppl 1):8-16.
  • Brunner PM, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25.
  • Whiteley J, et al. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1-7. [Epub ahead of print].
  • Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
  • Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858-873.
  • Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
  • Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  • de Bruin-Weller M, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083-1101.
  • Boguniewicz M. Biologic therapy for atopic dermatitis: moving beyond the practice parameter and guidelines. J Allergy Clin Immunol Pract. 2017;5(6):1477-1487.
  • Cotter DG, et al. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78(3S1):S53-S62.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Discuss atopic dermatitis pathophysiology, including clinically relevant molecular and cellular targets
  • Assess patients with atopic dermatitis longitudinally for uncontrolled symptoms, disease flares, comorbidities, and clinical responses to their current treatment regimens
  • Describe the clinical profiles of targeted biologic therapies for the treatment of moderate-to-severe atopic dermatitis
  • Optimize treatment regimens for patients with moderate-to-severe atopic dermatitis to reduce symptomatology, address comorbidities, maximize health-related quality of life, and minimize treatment-related side effects
  • Educate patients and caregivers to improve their understanding of atopic dermatitis to promote shared decision-making and treatment adherence

Faculty

Marjolein de Bruin-Weller, MD, PhD
Head, National Expertise Center for Atopic Dermatitis
Department of Dermatology/Allergology
University Medical Center Utrecht
Utrecht, The Netherlands



Eric L. Simpson, MD, MCR
Professor of Dermatology
Director, Clinical Research
Department of Dermatology
Oregon Health & Science University
Portland, Oregon, USA



Andreas Wollenberg, MD, PhD
Professor
Department of Dermatology and Allergy
Ludwig-Maximilian University of Munich
Munich, Germany


Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 70% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Marjolein de Bruin-Weller, MD, PhD

  • Consultant/Advisor: AbbVie Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme
  • Grant/Research Support: Regeneron Pharmaceuticals, Inc., Sanofi Genzyme.

Eric L. Simpson, MD, MCR

  • Consultant/Advisor: AbbVie Inc., Eli Lilly and Company, Galderma Laboratories, L.P., LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme.
  • Grant/Research Support: Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Vanda Pharmaceuticals Inc.

Andreas Wollenberg, MD, PhD

  • Consultant/Advisor: Almirall Limited, Beiersdorf AG, Galderma S.A., LEO Pharma Inc., L’Oréal S.A., MedImmune, LLC, Pierre Fabre Laboratories, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi-Aventis Europe S.A.S.
  • Grant/Research Support: Beiersdorf AG, LEO Pharma Inc.
  • Speakers Bureau: Almirall Limited, Anacor Pharmaceuticals, Inc., Astellas Pharma Europe Ltd, Beierdsorf AG, Bioderma Laboratoire Dermatologique, Celgene Corporation, Chugai Pharmaceutical Co., Ltd., Galderma S.A., Hans Karrer GMBH, LEO Pharma Inc., L’Oréal S.A., Meda AB, MedImmune, LLC, Merck Sharp & Dohme Corp., Novartis Pharma AG, Pierre Fabre Laboratories, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi-Aventis Europe S.A.S.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Stacey Ullman, MHS
Nothing to disclose

Ashley Marostica, RN, MSN
Nothing to disclose

Lindsay Borvansky
Nothing to disclose

Andrea Funk
Nothing to disclose

Liddy Knight
Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.